Key facts
- ARCS’s last known valuation is $14.1M (May 2025).
- It has raised $6.1M; the latest was Early Stage VC ($5.6M) in May 2025.
- Notable investors include Mitsubishi UFJ Capital, Mizuho Capital, Japan External Trade Organization, DEEPCORE, Mirai Cross — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for ARCS
- ·The full record, as it builds
Funding rounds
No funding rounds for ARCS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ARCS
Developer of reproductive technology designed for fertility treatment. The company develops technology to improve the quality and success rate of assisted reproductive medicine using AI and robot technology, enabling medical institutions to increase the number of treatment options for patients suffering from infertility.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2022
- Employees
- 20
- Website
- arcs-inc.jp/
- Ownership
- Privately Held (backing)
ARCS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ARCS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ARCS in its N-PORT filings yet. We sweep new filings monthly.